Scientist, Biologics Cell Line Development at Asimov

Boston, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Junior (1 to 2 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Synthetic BiologyIndustries

Requirements

Ph.D. in Biological Engineering, Cell Biology, Molecular Biology, or a related field with <3 years experience after graduation
Depth of knowledge in areas of biology relevant to how mammalian cells regulate transcription, translation, protein folding & assembly, intracellular trafficking and/or secretion
Interest in genetically engineering cells to support clinical development of human therapeutics
Established as an emerging innovator, interested in applying knowledge and curiosity to work collaboratively and cross-functionally to develop enhanced platforms for production of therapeutic proteins
Creative problem solver excited about driving the creation of industry-disruptive technology
Expert in spreadsheets such as Google Sheets or Excel
Ideally experienced with Spotfire, Google Apps Script (JavaScript) and/or BigQuery to facilitate data management and analysis
Experienced with electronic lab notebooks (Benchling) and meticulous documentation of experiments
Prior experience genetically engineering CHO cells to express mAbs & bsAbs is desirable but not required
Familiarity with cell culture liquid handling automation, ambr bioreactors, and/or ddPCR is a plus

Responsibilities

Perform CHO cell line development processes including transfection, cloning, characterization, and cell banking using state-of-the-art equipment
Drive innovation through the development of novel cell line development workflows and applications
Identify emerging practices for biologics cell line development and manufacturing to shape scientific strategies and develop improved workflows
Represent the cell line development team on cross-functional projects, making decisions for cell line activities
Effectively communicate results, progress, and plans
Conduct CHO-based cell line engineering for biologic therapeutics
Design complex experimental approaches to improve workflows and systems
Coordinate project efforts
Mentor junior scientists
Work closely with Asimov’s synthetic biology and process development teams

Skills

CHO Cell Line Development

Transfection

Cloning

Cell Characterization

Cell Banking

Synthetic Biology

Mammalian Cell Engineering

Molecular Biology

Cell Biology

Asimov

Synthetic biology solutions for biopharmaceuticals

About Asimov

Asimov operates in the synthetic biology field, providing a combination of cells, genes, and software to assist in advanced genetic design. Their products include cloud-based software that allows clients in the biopharmaceutical industry to design, simulate, and optimize genetic systems. Additionally, they offer engineered GMP host cells that are used for therapeutic applications. Asimov distinguishes itself from competitors by guaranteeing high titer cell lines for monoclonal antibodies with a promise of '4 g/L or it's free,' which reduces risk for their clients. The company's goal is to enable biopharma companies to produce high-quality protein therapeutics and scalable viral vectors efficiently, supported by their in-house expertise in synthetic biology and process development.

Boston, MassachusettsHeadquarters

2017Year Founded

$199.1MTotal Funding

SERIES_BCompany Stage

AI & Machine Learning, BiotechnologyIndustries

51-200Employees

Risks

Competition from LatchBio's code-free biocomputing infrastructure challenges Asimov's software offerings.

Integration of The Foundry may lead to potential cultural clashes and operational disruptions.

Rapid data generation in synthetic biology may strain Asimov's data processing capabilities.

Differentiation

Asimov offers a '4 g/L or it's free' promise for monoclonal antibodies.

The LV Edge Producer System eliminates GMP plasmid costs and reduces process complexity.

Asimov integrates synthetic biology, computer-aided design, and machine learning for genetic design.

Upsides

Stable cell line development reduces costs and increases scalability in lentiviral production.

Acquisition of The Foundry enhances Asimov's expertise in genetic design and engineering.

Growing biotech investments indicate a robust market for Asimov's engineered cell lines.

Land your dream remote job 3x faster with AI

Try Jobo Free